Addus HomeCare is a low-margin business with growth potential, but valuation estimates suggest a risk/reward imbalance for investors. See more on ADUS here.

The January effect, initially observed in small-cap stocks, has diminished over time, likely due to randomness rather than a ...

Treasury Inflation-Protected Securities offer a great risk-reward outlook, with PIMCO 15+ Year U.S. TIPS Index ...

Panagram AAA CLO ETF invests in AAA CLOs and comes from Panagram Structured Asset Management. Click here to read more about ...

Fox Factory's Q3 2024 revenue missed expectations due to macroeconomic conditions and reduced OEM forecasts. Read why FOXF ...

Read here for more on SMCI stock's struggles with equity or debt options, removal from index, reporting delays, and negative ...

Paycor HCM's new guidance indicates sustainable mid-teens recurring revenue growth. Click here to read why I've upgraded PYCR ...

NervGen's groundbreaking NVG-291 treatment for spinal cord injury is currently in trials with FDA Fast Track Designation.

CareDx has shown strong revenue growth and maintains a robust balance sheet. Read why CDNA stock is a prime candidate for my growth portfolio.

The current fears surrounding Google seem, in my opinion, overly inflated. Click here to read why GOOG stock remains a Buy.

We caution investors on Vistra, highlighting overvaluation despite growth and green initiatives. See why we suggest a hold on ...

Mastercard is a solid long-term investment with strong growth prospects, driven by its global reach and innovative business ...